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The common g-chain (gc) is a key component of multiple cytokine receptors. In this issue of Immunity, Hong
et al. (2014) demonstrate a unique function of gc as a secreted protein capable of inhibiting cytokine
responses and promoting autoimmunity.Many of the best-studied cytokines
in immunology—interleukin-2 (IL-2), IL-4,
IL-7, IL-9, IL-15, and IL-21—signal
through receptors that include the com-
mon g-chain (gc, or CD132) (Rochman
et al., 2009; Yamane and Paul, 2012).
This versatile protein associates with
cytokine-specific receptor chains in the
plasma membrane and plays a critical
role in receptor signaling through the
kinase JAK3, which binds to the cyto-
plasmic tail of gc (Figure 1, left). However,
while studying in vitro activated mouse
T cells, Hong et al. (2014) made the unex-
pected observation that gc appeared in
the supernatant. They quickly showed
that this soluble form of gc (sgc) arose
through alternative splicing, which led to
loss of the transmembrane and cyto-
plasmic tail and appearance of a unique
short sequence that includes a cysteine
available for disulfide bonding (Figure 1,
right; Hong et al., 2014).
To explore the relevance of this
finding, the investigators developed two
model systems that tested how sgc
overexpression or loss affected immune
homeostasis. Overexpression in T cells
led to a 2- to 3-fold increase in sgc
serum concentrations, but no qualitative
effects on T cell development, CD4+ and
CD8+ T cell numbers, or the frequency
and function of Treg cells. Yet there
was a substantial augmentation in the
frequency of freshly isolated CD4+
T cells capable of producing IL-17 or
IFN-g (but no change in the frequency
of cells making IL-4). Exploring whether
these changes had consequences for
inflammatory autoimmune disease, the
authors induced experimental auto-
immune encephalomyelitis (EAE) and
found that sgc transgenic mice devel-
oped greater numbers of CD4+ T cells
capable of making IFN-g and/or IL-17
in the spinal cord, with associatedhigher clinical scores for autoimmune
pathology. A second model was tested,
in which the authors reconstituted
gc-deficient mice with a transgene
encoding only the membrane form of
gc (mgc)—hence these animals were
unable to produce sgc. Consistent with
their other findings, these animals re-
sisted the induction of EAE and showed
reduced CNS invasion of IL-17- and
IFN-g-producing cells. Likewise, the
mgc-only mice were less susceptible to
induction of colitis after transfer of naive
CD4+ T cells, correlating with reduced
Th17 cell differentiation.
So how does soluble gc mediate these
effects? A key insight came when the
authors showed that sgc can bind IL-
2Rb chain (CD122) and IL-7Ra (CD127)
and can inhibit the T cell response to
IL-2. Optimal binding required dimeric
sgc and engagement with CD122 was
enhanced by IL-2 itself. This suggests
that sgc acts as a competitor for mgc
in association with key elements of the
cytokine receptors and—because sgc
does not participate in signaling—antag-
onizes the response to gc cytokines. This
could explain the bias toward Th17 cell
responses in the presence of sgc,
because IL-2 can inhibit Th17 cell differ-
entiation. Furthermore, the authors pro-
pose that the IL-7 receptor is also sus-
ceptible to antagonism by sgc, leading
to a reduction in thymocyte numbers
and survival of naive T cells in sgc trans-
genic mice.
The implications of these findings are
numerous. The production of sgc by
T cells is stimulated by activation, sug-
gesting a potential role of sustained sgc
production in feedback inhibition of the
IL-2 response (while also exacerbating
Th17 cell polarization). At physiological
amounts of sgc, these effects may be
beneficial for the immune response toImmunityforeign antigens, while also enhancing
the risk of increased pathology during
autoimmunity. It will be interesting to
see how sgc expression impacts the
response to infectious agents by CD4+
and CD8+ T cells and by other lymphocyte
populations (several of which utilize gc
cytokine receptors).
Further studies will be needed to under-
stand how sgc shapes T cell differentia-
tion. For example, whereas IL-2R stimula-
tion impairs the generation of Th17 cells,
signals through IL-21R—another gc
cytokine receptor—are needed to drive
development of Th17 cell responses dur-
ing EAE induction (Nurieva et al., 2007)
and are presumably less severely
impaired by sgc. Determining the hierar-
chy of inhibition for distinct gc receptors
may help predict the effects of sgc
expression. Also, it is somewhat surpris-
ing that altered sgc expression does not
have amore profound effect on Treg cells,
which are highly dependent on IL-2 for
their normal function and homeostasis.
Indeed, the capacity of sgc to inhibit the
IL-2 response by cells utilizing the high-
affinity IL-2R (which includes CD25) has
yet to be shown.
On a related point, it is unclear whether
the inhibitory function of sgc is deter-
mined primarily through paracrine or
autocrine pathways: if an autocrine model
applies, T cells making abundant sgc
might be the most strongly inhibited—
suggesting that sgc acts as a rheostat
for regulating an individual activated
T cell’s response to the gc cytokines it
encounters. In contrast, a paracrine role
might not only affect bystander activated
T cells, but could also impact numerous
cells in the immune system—including
immature and naive conventional lym-
phocytes, as well as some innate
lymphoid cells that require signaling
through gc-cytokine receptors (Spits and40, June 19, 2014 ª2014 Elsevier Inc. 859
Figure 1. Telling Tails
In resting T cells (left), gc is produced as a membrane bound form (mgc) that joins with cytokine-specific
receptor chains to mediate cytokine binding and receptor signaling though activation of JAK kinases that
are associated with the cytoplasmic tails of the receptors (indicated by circles). In activated T cells, how-
ever, alternative splicing also generates sgc, a secreted form of gc (right). sgc lacks the transmembrane
and cytoplasmic tail and includes a novel C terminus (purple), which includes a cysteine that is probably
involved in sgc dimer formation. sgc is thought to act as a competitive antagonist for mgc binding to cyto-
kine-specific receptor chains, thereby blocking cytokine receptor signaling. Some gc cytokine receptors
include a third receptor chain (not shown).
Immunity
PreviewsDi Santo, 2011). In this paracrine scenario,
serum concentrations of sgc would need
to reach the threshold for the proposed
inhibitory effects. Hong et al. (2014)
measured a relatively low affinity for the
gc-CD122 interaction, and low amounts
of serum sgc in normal animals, which
might argue against this model—but a
more relevant measurement may be con-
centrations of sgc in tissues, which are yet
to be determined. Assessing whether
some or all the immunoregulatory effects
of sgc are cell autonomous will be a crit-
ical step, in addition to exploring whether
sgc production differs in distinct T cell
subsets—and, potentially, other lympho-
cyte populations—at steady state and860 Immunity 40, June 19, 2014 ª2014 Elsevafter activation (in both conventional and
autoimmune situations).
Finally, it will be exciting to extend these
findings to humans. Hong et al. (2014)
found transcripts for a human sgc with
some of the same key features as the
mouse version (including a cysteine near
the novel C-terminus, available for forma-
tion of disulfide bonded dimer), and it will
be interesting to examine sgc production
in infectious and autoimmune diseases
of humans. A tantalizing hint of potential
relevance is indicated in reports that the
inflamed joints of rheumatoid arthritis
patients contain abundant soluble gc,
although the molecular form of that
secreted gc (and hence its relationshipier Inc.to sgc) was not described in that study
(Nishio et al., 2001).
This report by Hong et al. (2014) un-
covers a unique role for gc. Whereas the
key role of the membrane-bound form in
promoting cytokine receptor signaling is
well known, the production of a soluble
form capable of behaving as a decoy for
this same process is intriguing. Many
cell surface receptors (including other
cytokine receptor chains) can also be
shed or produced as secreted forms, but
the fact that gc engages with so many
cytokine receptors suggests that it may
serve to regulate diverse aspects of the
immune response. If so, this pioneering
report by Hong et al. (2014) may be seen
as the tip (or, more appropriately, the
tail) of the iceberg.REFERENCES
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